CD274 and cancer: Immune checkpoint inhibitors that target the inhibitory proteins like programmed death-ligand 1 (PD-L1) on cancer cells and cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T cells have received FDA approval for the treatment of advanced HCC, including Atezolizumab, Tremelimumab, Pembrolizumab, and Nivolumab [25].